NEOGEN CORP

NEOG

Explore Our Financial Data > Companies > NEOGEN CORP
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
NEOG
CIK0000711377
SIC2835
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupIn Vitro, In Vivo Diagnostic Substances

Contact

Address620 LESHER PLACE, LANSING, MI, 48912
Website neogen.com
Phone5173729200
CEOJohn E. Adent
Employees2,110

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$894.66 million
Pre-Tax Income$-1.13 billion
Net Income$-1.09 billion
Net Income to Common$-1.09 billion
EPS$-5.03
View All
Balance Sheet
Cash$129.00 million
Assets$3.44 billion
Liabilities$1.37 billion
Common Equity$2.07 billion
Liabilities & Equity$3.44 billion
View All
Cash Flow Statement
Net Income$-1.09 billion
Cash From Operating Activities$58.24 million
Cash From Investing Activities$-99.20 million
Cash From Financing Activities$-1.60 million
Change in Cash$-41.61 million
View All
Calculations
NOPAT$-742.70 million
EBITDA$-935.71 million
Price to EarningsN/A
Price to Book$0.54
ROE-41.88%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

[Latest] Global Arabinogalactan Market Size/Share Worth USD 312 Million by 2034 at a 4.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Arabinogalactan Market size & share revenue was valued at approximately USD 201 Million in 2024 and is expected to reach USD 209 Million in 2025 and is expected to reach around USD 312 Million by 2034, at a CAGR of 4.5% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are ACTYLIS, Ametis JSC, Ataman Kimya A.

Article Link

Q2 Earnings Highlights: Neogen (NASDAQ:NEOG) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - diversified industry, including Neogen (NASDAQ:NEOG) and its peers.

Article Link

Neogen Full Year 2025 Earnings: EPS Misses Expectations

Neogen ( NASDAQ:NEOG ) Full Year 2025 Results Key Financial Results Revenue: US$894.7m (down 3.2% from FY 2024). Net...

Article Link

Neogen (NEOG) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Neogen (NEOG) give insight into how the company performed in the quarter ended May 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Article Link

Neogen Corp (NEOG) Q4 2025 Earnings Call Highlights: Navigating Challenges with Strategic ...

Despite a core revenue decline, Neogen Corp (NEOG) leverages strategic divestitures and regulatory support to position for future growth.

Article Link